Mass spectrometry-based plasma proteomics: State of the art and future outlook

Expert Review of Proteomics

Volumn 11, Issue 4, 2014, Pages 431-448

  Pernemalm, Maria ^a   Lehtiö, Janne ^a  

^a SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

biomarkers; fractionation; high abundance protein depletion; mass spectrometry; MRM; plasma; proteomics; quantitation; serum; SRM; SWATH

Indexed keywords

ANTIBODY; PLASMA PROTEIN; GLYCOPROTEIN; PROTEOME;

AFFINITY CHROMATOGRAPHY; ANTIBODY AFFINITY; BLOOD ANALYSIS; COMPLEMENT ACTIVATION; DEGLYCOSYLATION; FRACTIONATION; GLYCOSYLATION; GRAFT VERSUS HOST REACTION; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MASS SPECTROMETRY BASED PLASMA PROTEOMIC; NONHUMAN; PLASMA VOLUME; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; TANDEM MASS SPECTROMETRY; ANIMAL; CHEMISTRY; DEVICES; PLASMA; PROCEDURES;

ANIMALS; CHROMATOGRAPHY, LIQUID; GLYCOPROTEINS; HUMANS; MASS SPECTROMETRY; PLASMA; PROTEOME;

EID: 84904305923     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.901157     Document Type: Review

References (116)

1. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1(11):845-67
2. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5(13):3226-45 (Pubitemid 41192032)
3. States DJ, Omenn GS, Blackwell TW, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006;24(3):333-8 (Pubitemid 43372157)
4. Farrah T, Deutsch EW, Omenn GS, et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 2011; 10(9):M110.006353
5. Farrah T, Deutsch EW, Omenn GS, et al. State of the human proteome in 2013 as viewed through peptideatlas: comparing the kidney, urine, and plasma proteomes for the biology-and disease-driven human proteome project. J Proteome Res 2014; 13(1):60-75
6. Selvaraju S, Rassi ZE. Liquid-phase-based separation systems for depletion, prefractionation and enrichment of proteins in biological fluids and matrices for in-depth proteomics analysis-an update covering the period 2008-2011. Electrophoresis 2012;33(1):74-88
7. Polaskova V, Kapur A, Khan A, et al. High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 2010; 31(3):471-82
8. Shuford CM, Hawkridge AM, Burnett JC, Muddiman DC. Utilizing spectral counting to quantitatively characterize tandem removal of abundant proteins (TRAP) in human plasma. Anal Chem 2010;82(24): 10179-85
9. Cao Z, Yende S, Kellum JA, Robinson RA. Additions to the human plasma proteome via a tandem MARS depletion iTRAQ-based workflow. Int J Proteomics 2013;2013:654356
10. Tan SH, Mohamedali A, Kapur A, Baker MS. Ultradepletion of human plasma using chicken antibodies: a proof of concept study. J Proteome Res 2013;12(6):2399-413
11. Shi T, Zhou JY, Gritsenko MA, et al. IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery. Methods 2012;56(2):246-53
12. Qian WJ, Kaleta DT, Petritis BO, et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 2008;7(10): 1963-73
13. Jones KA, Kim PD, Patel BB, et al. Immunodepletion plasma proteomics by tripleTOF 5600 and Orbitrap elite/LTQ-Orbitrap Velos/Q exactive mass spectrometers. J Proteome Res 2013;12(10): 4351-65
14. Tu C, Rudnick PA, Martinez MY, et al. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010;9(10):4982-91
15. Bellei E, Bergamini S, Monari E, et al. High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids 2011;40(1):145-56
16. Gundry RL, Fu Q, Jelinek CA, et al. Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl 2007; 1(1):73-88
17. Gundry RL, White MY, Nogee J, et al. Assessment of albumin removal from an immunoaffinity spin column: critical implications for proteomic examination of the albuminome and albumin-depleted samples. Proteomics 2009;9(7):2021-8
18. Lowenthal MS, Mehta AI, Frogale K, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005;51(10):1933-45 (Pubitemid 41368193)
19. Pernemalm M, Orre LM, Lengqvist J, et al. Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery. J Proteome Res 2008;7(7):2712-22
20. Yadav AK, Bhardwaj G, Basak T, et al. A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery. PLoS One 2011;6(9):e24442
21. Patel BB, Barrero CA, Braverman A, et al. Assessment of two immunodepletion methods: off-target effects and variations in immunodepletion efficiency may confound plasma proteomics. J Proteome Res 2012; 11(12):5947-58
22. Holewinski RJ, Jin Z, Powell MJ, et al. A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid. Proteomics 2013;13(5): 743-50
23. Boschetti E, Righetti PG. The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteomics 2008;71(3):255-64
24. Millioni R, Tolin S, Puricelli L, et al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One 2011;6(5):e19603
25. Jian G, Liu Y, He X, et al. Click chemistry: a new facile and efficient strategy for the preparation of Fe3O4 nanoparticles covalently functionalized with IDA-Cu and their application in the depletion of abundant protein in blood samples. Nanoscale 2012;4(20):6336-42
26. Wu SL, Taylor AD, Lu Q, et al. Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line. Mol Cell Proteomics 2013;12(5):1239-49
27. Ruhaak LR, Nguyen UT, Stroble C, et al. Enrichment strategies in glycomics-based lung cancer biomarker development. Proteomics Clin Appl 2013. [Epub ahead of print]
28. Tousi F, Bones J, Hancock WS, Hincapie M. Differential chemical derivatization integrated with chromatographic separation for analysis of isomeric sialylated N-glycans: a nano-hydrophilic interaction liquid chromatography-MS platform. Anal Chem 2013;85(17):8421-8
29. Wang H, Wong CH, Chin A, et al. Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications. Nat Protoc 2011;6(3):253-69
30. Zielinska DF, Gnad F, Wisniewski JR, Mann M. Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 2010;141(5): 897-907
31. Boersema PJ, Geiger T, Wisniewski JR, Mann M. Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples. Mol Cell Proteomics 2013;12(1):158-71
32. Zhou H, Froehlich JW, Briscoe AC, Lee RS. The GlycoFilter: a simple and comprehensive sample preparation platform for proteomics, N-glycomics and glycosylation site assignment. Mol Cell Proteomics 2013; 12(10):2981-91
33. Zhang H, Li XJ, Martin DB, Aebersold R Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21(6): 660-6 (Pubitemid 36638093)
34. Cima I, Schiess R, Wild P, et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci USA 2011;108(8):3342-7
35. Wada Y, Tajiri M, Yoshida S. Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. Anal Chem 2004; 76(22):6560-5 (Pubitemid 39507245)
36. Zhao X, Ma C, Han H, et al. Comparison and optimization of strategies for a more profound profiling of the sialylated N-glycoproteomics in human plasma using metal oxide enrichment. Anal Bioanal Chem 2013;405(16):5519-29
37. Ueda K. Glycoproteomic strategies: from discovery to clinical application of cancer carbohydrate biomarkers. Proteomics Clin Appl 2013. [Epub ahead of print]
38. Drake PM, Cho W, Li B, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2010;56(2):223-36
39. Fanayan S, Hincapie M, Hancock WS. Using lectins to harvest the plasma/serum glycoproteome. Electrophoresis 2012;33(12): 1746-54
40. Gevaert K, Goethals M, Martens L, et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol 2003;21(5):566-9 (Pubitemid 36532024)
41. Kleifeld O, Doucet A, auf dem Keller U, et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat Biotechnol 2010;28(3):281-8
42. Wildes D, Wells JA. Sampling the N-terminal proteome of human blood. Proc Natl Acad Sci USA 2010;107(10):4561-6
43. Guryca V, Lamerz J, Ducret A, Cutler P. Qualitative improvement and quantitative assessment of N-terminomics. Proteomics 2012; 12(8): 1207-16
44. Poetz O, Hoeppe S, Templin MF, et al. Proteome wide screening using peptide affinity capture. Proteomics 2009;9(6): 1518-23
45. Volk S, Schreiber TD, Eisen D, et al. Combining ultracentrifugation and peptide termini group-specific immunoprecipitation for multiplex plasma protein analysis. Mol Cell Proteomics 2012;11(7):O111.015438
46. Gautam P, Nair SC, Ramamoorthy K, et al. Analysis of human blood plasma proteome from ten healthy volunteers from Indian population. PLoS One 2013;8(8):e72584
47. Li RX, Ding YB, Zhao SL, et al. Secretome-derived isotope tags (SDIT) reveal adipocyte-derived apolipoprotein C-I as a predictive marker for cardiovascular disease. J Proteome Res 2012;11(5):2851-62
48. Beer LA, Wang H, Tang HY, et al. Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. PLoS One 2013;8(3):e60129
49. Garbis SD, Roumeliotis TI, Tyritzis SI, et al. A novel multidimensional protein identification technology approach combining protein size exclusion prefractionation, peptide zwitterion-ion hydrophilic interaction chromatography, and nano-ultraperformance RP chromatography/nESI-MS2 for the in-depth analysis of the serum proteome and phosphoproteome: application to clinical sera derived from humans with benign prostate hyperplasia. Anal Chem 2011;83(3):708-18
50. Ueda K, Tatsuguchi A, Saichi N, et al. Plasma low-molecular-weight proteome profiling identified neuropeptide-y as a prostate cancer biomarker polypeptide. J Proteome Res 2013;12(10):4497-506
51. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19(3): 242-7 (Pubitemid 32220565)
52. Wolters DA, Washburn MP, Yates JR. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001;73(23): 5683-90 (Pubitemid 33126725)
53. Addona TA, Shi X, Keshishian H, et al. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol 2011;29(7):635-43
54. Amon LM, Pitteri SJ, Li CI, et al. Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER + breast cancer. Cancer Res 2012;72(8): 1935-42
55. Kelly-Spratt KS, Pitteri SJ, Gurley KE, et al. Plasma proteome profiles associated with inflammation, angiogenesis, and cancer. PLoS One 2011;6(5):e19721
56. Pitteri SJ, Kelly-Spratt KS, Gurley KE, et al. Tumor microenvironment- derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 2011;71(15): 5090-100
57. Taguchi A, Politi K, Pitteri SJ, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011;20(3):289-99
58. Wang H, Clouthier SG, Galchev V, et al. Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005;4(5):618-25 (Pubitemid 40862241)
59. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010; 2(13):13ra12
60. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011; 118(25):6702-8
61. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013;369(6): 529-39
62. Cao Z, Tang HY, Wang H, et al. Systematic Comparison of Fractionation Methods for In-depth Analysis of Plasma Proteomes. J Proteome Res 2012;11(6): 3090-100
63. Pernemalm M, De Petris L, Eriksson H, et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics 2009;9(13):3414-24
64. Pernemalm M, Lehtiö J. A novel prefractionation method combining protein and peptide isoelectric focusing in immobilized pH gradient strips. J Proteome Res 2013;12(2):1014-19
65. Pernemalm M. Narrow-range peptide isoelectric focusing as peptide prefractionation method prior to tandem mass spectrometry analysis. Methods Mol Biol 2013;1023:3-11
66. Eriksson H, Lengqvist J, Hedlund J, et al. Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms. Proteomics 2008;8(15): 3008-18
67. Heller M, Michel PE, Morier P, et al. Two-stage Off-Gel isoelectric focusing: protein followed by peptide fractionation and application to proteome analysis of human plasma. Electrophoresis 2005;26(6): 1174-88 (Pubitemid 40514809)
68. Zeng Z, Hincapie M, Pitteri SJ, et al. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal Chem 2011; 83(12):4845-54
69. Cargile BJ, Bundy JL, Freeman TW, Stephenson JL. Gel based isoelectric focusing of peptides and the utility of isoelectric point in protein identification. J Proteome Res 2004;3(1):112-19 (Pubitemid 38233458)
70. Branca RM, Orre LM, Johansson HJ, et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat Methods 2014;11(1):59-62
71. Schenk S, Schoenhals GJ, de Souza G, Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics 2008;1:41
72. Tang HY, Beer LA, Chang-Wong T, et al. A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res 2012;11(2):678-91
73. Whiteaker JR, Lin C, Kennedy J, et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 2011;29(7):625-34
74. Shi T, Su D, Liu T, et al. Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 2012;12(8):1074-92
75. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012;9(6):555-66
76. Domanski D, Percy AJ, Yang J, et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 2012;12(8):1222-43
77. Percy AJ, Chambers AG, Yang J, et al. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim Biophys Acta 2013. [Epub ahead of print]
78. Percy AJ, Chambers AG, Yang J, Borchers CH. Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. Proteomics 2013;13(14): 2202-15
79. Percy AJ, Parker CE, Borchers CH. Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies. Bioanalysis 2013;5(22): 2837-56
80. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27(7): 633-41
81. Kuhn E, Whiteaker JR, Mani DR, et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics 2012;M111.013854
82. Percy AJ, Chambers AG, Yang J, et al. Method and platform standardization in MRM-based quantitative plasma proteomics. J Proteomics 2013;95:66-76
83. Percy AJ, Chambers AG, Smith DS, Borchers CH. Standardized protocols for quality control of MRM-based plasma proteomic workflows. J Proteome Res 2013; 12(1):222-33
84. Gallien S, Bourmaud A, Kim SY, Domon B. Technical considerations for large-scale parallel reaction monitoring analysis. J Proteomics 2013. [Epub ahead of print]
85. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5(4):573-88
86. Kennedy JJ, Abbatiello SE, Kim K, et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods 2014;11(2): 149-55
87. Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013;5(207): 207ra142
88. Hüttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med 2012;4(142):142ra194
89. Anderson NL, Anderson NG, Haines LR, et al. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004;3(2):235-44 (Pubitemid 38500990)
90. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010;9(1): 184-96
91. Nicol GR, Han M, Kim J, et al. Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics 2008; 7(10):1974-82
92. Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28(12):1248-50
93. Cerciello F, Choi M, Nicastri A, et al. Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. Clin Proteomics 2013; 10(1):16
94. Ahn YH, Lee JY, Kim YS, et al. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res 2009;8(9):4216-24
95. Shi T, Fillmore TL, Sun X, et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci USA 2012;109(38):15395-400
96. Shi T, Sun X, Gao Y, et al. Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. J Proteome Res 2013;12(7): 3353-61
97. Keshishian H, Addona T, Burgess M, et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007;6(12): 2212-29
98. DeSouza LV, Taylor AM, Li W, et al. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J Proteome Res 2008;7(8):3525-34
99. Fortin T, Salvador A, Charrier JP, et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics 2009;8(5):1006-15
100. Rafalko A, Dai S, Hancock WS, et al. Development of a Chip/Chip/SRM platform using digital chip isoelectric focusing and LC-Chip mass spectrometry for enrichment and quantitation of low abundance protein biomarkers in human plasma. J Proteome Res 2012;11(2):808-17
101. Cargile BJ, Talley DL, Stephenson JL. Immobilized pH gradients as a first dimension in shotgun proteomics and analysis of the accuracy of pI predictability of peptides. Electrophoresis 2004;25(6): 936-45 (Pubitemid 38401387)
102. Liu Y, Hüttenhain R, Surinova S, et al. Quantitative measurements of N-linked glycoproteins in human plasma by SWATH-MS. Proteomics 2013;13(8): 1247-56
103. Fortin T, Salvador A, Charrier JP, et al. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal Chem 2009;81(22):9343-52
104. Jeudy J, Salvador A, Simon R, et al. Overcoming biofluid protein complexity during targeted mass spectrometry detection and quantification of protein biomarkers by MRM cubed (MRM(3)). Anal Bioanal Chem 2014;406(4):1193-200
105. Johansson A, Enroth S, Palmblad M, et al. Identification of genetic variants influencing the human plasma proteome. Proc Natl Acad Sci USA 2013;110(12):4673-8
106. Lauc G, Essafi A, Huffman JE, et al. Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1a as a master regulator of plasma protein fucosylation. PLoS Genet 2010; 6(12):e1001256
107. Eichelbaum K, Winter M, Berriel Diaz M, et al. Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat Biotechnol 2012; 30(10):984-90
108. Gref R, Lück M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000;18(3-4):301-13 (Pubitemid 30479870)
109. Tenzer S, Docter D, Rosfa S, et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011;5(9):7155-67
110. Ostergaard O, Nielsen CT, Iversen LV, et al. Quantitative proteome profiling of normal human circulating microparticles. J Proteome Res 2012;11(4):2154-63
111. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009;6(3):267-83
112. Kalra H, Adda CG, Liem M, et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 2013;13(22):3354-64
113. Neiman M, Fredolini C, Johansson H, et al. Selectivity analysis of single binder assays used in plasma protein profiling. Proteomics 2013;13(23-24):3406- 10
114. Ayoglu B, Häggmark A, Neiman M, et al. Systematic antibody and antigen-based proteomic profiling with microarrays. Expert Rev Mol Diagn 2011;11(2):219-34
115. Darmanis S, Nong RY, Hammond M, et al. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol Cell Proteomics 2010;9(2): 327-35
116. Darmanis S, Nong RY, Vänelid J, et al. ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing. PLoS One 2011; 6(9):e25583